Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015

S A McNeil; M K Andrew; L Ye; F Haguinet; T F Hatchette; M ElSherif; J LeBlanc; A Ambrose; A McGeer; J E McElhaney; M Loeb; D MacKinnon-Cameron; R Sharma; G Dos Santos; V Shinde; Collective on behalf of the Investigators of the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN)

doi:10.2807/1560-7917.ES2015.20.5.21024

Research articles Open Access

Like 0

Download

Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015

S A McNeil¹, M K Andrew¹, L Ye¹, F Haguinet², T F Hatchette¹, M ElSherif¹, J LeBlanc¹, A Ambrose¹, A McGeer³, J E McElhaney⁴, M Loeb⁵, D MacKinnon-Cameron¹, R Sharma⁶, G Dos Santos⁷, V Shinde⁸, Collective on behalf of the Investigators of the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN)⁹
View Affiliations Hide Affiliations

Affiliations: ¹ Canadian Center for Vaccinology, IWK Health Centre and Capital Health, Dalhousie University, Halifax, Nova Scotia, Canada ² GlaxoSmithKline Vaccines, Wavre, Belgium ³ Mount Sinai Hospital, Toronto, Ontario, Canada ⁴ Advanced Medical Research Institute of Canada, Sudbury, Ontario, Canada ⁵ McMaster University, Hamilton, Ontario, Canada ⁶ GlaxoSmithKline Vaccines, Mississauga, Ontario, Canada ⁷ Business & Decision Life Sciences (on behalf of GlaxoSmithKline Vaccines), Brussels, Belgium ⁸ GlaxoSmithKline Vaccines, King of Prussia, Pennsylvania, United States ⁹ Investigators in the network (www.cirnetwork.ca) are listed at the end of the article

Correspondence:
S McNeil
shelly.mcneil cdha.nshealth.ca
View Citation Hide Citation

Citation style for this article: McNeil S A, Andrew M K, Ye L, Haguinet F, Hatchette T F, ElSherif M, LeBlanc J, Ambrose A, McGeer A, McElhaney J E, Loeb M, MacKinnon-Cameron D, Sharma R, Dos Santos G, Shinde V, on behalf of the Investigators of the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN) Collective. Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015. Euro Surveill. 2015;20(5):pii=21024. https://doi.org/10.2807/1560-7917.ES2015.20.5.21024 Received: 23 Jan 2015

Abstract

The 2014/15 influenza season in Canada has been characterised to date by early and intense activity dominated by influenza A(H3N2). A total of 99.0% (593/599) hospitalisations for laboratory-confirmed influenza with a known influenza virus type enrolled in sentinel hospitals of the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network were due to influenza A. Of the 216 with a known subtype, influenza A(H3N2) accounted for 99.1% (n=214). Interim unmatched vaccine effectiveness (VE) estimates adjusted for age and presence of one or more medical comorbidities were determined by test-negative case-control design to be ?16.8% (90% confidence interval (CI): ?48.9 to 8.3) overall and ?22.0% (90% CI: ?66.5 to 10.7) for laboratory-confirmed influenza A(H3N2). Among adults?aged under?65 years, the overall VE was 10.8% (90% CI: ?50.2 to 47.0) while in adults?aged 65 years or older, the overall VE was ?25.4% (90% CI: ?65.0 to 4.6). .